Brunswick Corporation vs Novo Nordisk A/S — how do they compare? Brunswick Corporation trades at $81.32 (market cap $5.28B), while Novo Nordisk A/S trades at $46.28 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 39.4× Brunswick Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| BC | NVO | |
|---|---|---|
Market Cap | $5.28B | $207.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $89.22 | $63.98 |
52-Week Low | $58.75 | $35.29 |
Enterprise Value | $7.28B | $222.55B |
Dividend Yield | 2.16% | 3.81% |
Signals from Pluang's Aura AI — not financial advice
Brunswick Corporation (BC) trades at $79.54, down 1.11% on the day, with strong analyst support showing 22 buy ratings and a consensus price target of $85.33. Recent Q2 2026 earnings beat expectations with $1.56 EPS versus $1.19 expected, though the company posted a net loss of $137.3 million in 2025. Technical indicators show a bullish trend with support at $80 and resistance at $82, while fundamentals reveal mixed profitability with negative margins but positive cash flow from operations of $562.1 million.
The outlook remains cautiously optimistic given strong institutional backing and recent earnings beats, though investors face risks from negative profit margins and elevated P/E ratio of 73.92. The stock offers potential upside to analyst targets but requires monitoring of profitability improvements and debt management amid competitive pressures in the marine industry.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →